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ABSTRACT
Objective: Our aim was to evaluate the safety, reactogenicity, and immunogenicity of an
investigational malaria vaccine.
Design: This was an age-stratified phase Ib, double-blind, randomized, controlled, dose-
escalation trial. Children were recruited into one of three cohorts (dosage groups) and
randomized in 2:1 fashion to receive either the test product or a comparator.
Setting: The study was conducted in a rural population in Kombewa Division, western Kenya.
Participants: Subjects were 135 children, aged 12–47 mo.
Interventions: Subjects received 10, 25, or 50 lg of falciparum malaria protein 1 (FMP1)
formulated in 100, 250, and 500 lL, respectively, of AS02A, or they received a comparator
(Imovaxt rabies vaccine).
Outcome Measures: We performed safety and reactogenicity parameters and assessment
of adverse events during solicited (7 d) and unsolicited (30 d) periods after each vaccination.
Serious adverse events were monitored for 6 mo after the last vaccination.
Results: Both vaccines were safe and well tolerated. FMP1/AS02A recipients experienced
significantly more pain and injection-site swelling with a dose-effect relationship. Systemic
reactogenicity was low at all dose levels. Hemoglobin levels remained stable and similar across
arms. Baseline geometric mean titers were comparable in all groups. Anti-FMP1 antibody titers
increased in a dose-dependent manner in subjects receiving FMP1/AS02A; no increase in anti-
FMP1 titers occurred in subjects who received the comparator. By study end, subjects who
received either 25 or 50 lg of FMP1 had similar antibody levels, which remained significantly
higher than that of those who received the comparator or 10 lg of FMP1. A longitudinal mixed
effects model showed a statistically significant effect of dosage level on immune response
(F3,1047 ¼ 10.78, or F3, 995 ¼ 11.22, p , 0.001); however, the comparison of 25 lg and 50 lg
recipients indicated no significant difference (F1,1047 ¼ 0.05; p ¼ 0.82).
Conclusions: The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed 12- to
47-mo-old children and the magnitude of immune response of the 25 and 50 lg doses was
superior to that of the 10 lg dose.
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PLoS CLINICAL TRIALSINTRODUCTION
The world struggles to come to terms with the immensity of
the public health, economic, and political consequences of
malaria morbidity and mortality. Although no inhabited
continent is unaffected, Africa is particularly hard hit.
Annually, over half a billion Plasmodium falciparum infections
occur worldwide, leading to between 1 and 2 million deaths in
sub-Saharan Africans—most of them children [1–3]. The
proportion of total mortality attributable to malaria in this
pediatric population has increased in recent years because of
a general breakdown of public health services in many areas,
antimalarial drug resistance, interactions with the human
immunodeﬁciency virus, and (perhaps) global climate change
[4]. Nearly 100 candidate malaria vaccines are currently in
various stages of evaluation [5], and a pre-erythrocytic (pre-
blood stage, liver-stage) vaccine candidate, known as RTS,S,
has recently demonstrated efﬁcacy against clinical and severe
disease in children in Mozambique [6,7]. An alternative to
such pre-erythrocytic vaccines is the targeting of antigens
that are expressed during the erythrocytic (blood) stage of the
parasite life cycle. The rationale for such an erythrocytic
stage vaccine is based on the observation that natural
protection against clinical disease in adults and in young
children depends upon maintenance of high antibody levels
to antigens present on the form of the parasite (the
merozoite) that circulates in the bloodstream [8,9]. The P.
falciparum merozoite surface protein 1 (MSP-1) is a 195-kDa
protein that is proteolytically cleaved to yield four fragments,
which are associated with each other through noncovalent
interactions on the merozoite surface. Among them is the
carboxy-terminal 42-kDa fragment known as MSP-142 [10,11].
Secondary processing of the 42-kDa fragment into 19-kDa
and 33-kDa fragments is thought important for merozoite
invasion [12]. Individuals living under high malaria trans-
mission develop anti-MSP-142 and anti-MSP-119 antibodies
that inhibit parasite growth in vitro [13]. Moreover, inocu-
lation of Aotus monkeys with a recombinant MSP-142 and
potent adjuvant can confer protection against blood-stage
challenge with P. falciparum [14–16]. In human subjects, the
candidacy of MSP-142 as a potentially efﬁcacious malaria
vaccine is further supported by epidemiologic studies
demonstrating that antibodies to the relatively conserved
domains are associated with a diminution of P. falciparum
disease severity [9,17] and by the ﬁnding that the majority of
antibodies active in growth inhibition in sera from endemic
areas are p19 speciﬁc [18].
The MSP-142 of the 3D7 clone of P. falciparum has been
formulated into a ﬁnal test product, termed the falciparum
malaria protein 1 (FMP1) [19], and combined with Glaxo-
SmithKline’s proprietary adjuvant AS02A [20]. The safety and
immunogenicity of the FMP1/AS02A formulation has been
conﬁrmed in two phase I trials conducted in the United
States [21] and in phase I trials in malaria-experienced
populations in western Kenya [22] and Mali (C. Plowe,
personal communication). The present study, a phase Ib trial
in young children subject to intense malaria transmission,
follows up the previous adult trial in the same area of western
Kenya. It is part of our long-term malaria vaccine develop-
ment plan that aims to develop products to prevent malaria
morbidity and mortality in infants and young children in
malaria endemic areas.
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Editorial Commentary
Background: Malaria is thought to kill between 1 and 2 million people
each year in sub-Saharan Africa; most of these are young children under
the age of five, who are particularly prone to developing clinical malaria
because their immunity is not yet developed. Many groups of researchers
around the world are developing candidate vaccines of different types
that it is hoped would protect against malaria. One of these types is a
‘‘blood-stage’’ vaccine, which would prevent parasite multiplication in
red blood cells. A candidate blood-stage vaccine is FMP1/AS02A, which is
designed to raise an immune response against a particular protein
(merozoite surface protein-1) on the surface of the blood-stage infectious
form of the malaria parasite. In early-stage clinical trials performed in
people not exposed to malaria (healthy volunteers in the United States)
and in African adults who were exposed to malaria, this candidate
vaccine has already been shown to be safe and to bring about an
immune response. As part of the next stage in developing this vaccine, a
group of researchers next wanted to see whether the vaccine was also
safe and brought about an immune response in the population most in
need of a vaccine: young children living in an African region with very
intense malaria transmission. Therefore, as reported here, this group
performed a small trial in western Kenya, recruiting 135 children under 5
y of age to receive either the FMP1/AS02A vaccine (at three different
doses) or rabies vaccine for comparison (thus ensuring that children in
the control arm got some benefit from being in the trial). The outcomes
that the researchers were interested in were primarily adverse events,
which they categorized using a standard questionnaire at up to 7 d after
vaccination; unsolicited events reported up to 30 d after vaccination; and,
finally, any serious events occurring up to 8 mo later. The researchers also
examined antibody responses to the FMP1/AS02A vaccine.
What this trial shows: Participants who received the FMP1/AS02A
vaccine (as compared to the rabies vaccine) experienced more
immediate symptoms, such as pain and swelling at the injection site.
Most participants reported unsolicited events during follow-up, but the
proportion of participants with adverse events did not seem to be
different between the FMP1/AS02A vaccine groups and the rabies
vaccine group. Unsolicited outcomes that were reported included, for
example, clinical malaria, upper respiratory tract infections, and a few
events that were thought to be related to the vaccines, such as fever and
eczema. A few serious adverse events occurred up to 8 mo after
vaccination, but the numbers did not seem to be different between the
FMP1/AS02A and rabies vaccine groups, and the events were not judged
to be related to vaccination. Finally, participants who received the FMP1/
AS02A vaccine raised an antibody response to the vaccine, which was
highest in those who received the highest vaccine dose. The researchers
concluded that this vaccine was safe and brought about an immune
response in the group of malaria-exposed children studied.
Strengths and limitations: The trial was conducted in a population that
is likely to benefit from the vaccine, if it is shown to be effective in further
studies. Therefore, the data obtained from this study will be informative
in helping to design future trials on FMP1/AS02A. The randomization
procedures used in this study were appropriate, and in particular
participants of different ages were equally distributed to the different
intervention groups, helping to minimize bias. Procedures were also set
up to prevent participants and staff giving the vaccines and collecting
data from knowing which interventions participants had received.
However, the number of participants recruited into the trial was small,
and it therefore was not powered to detect anything other than large
differences in rates of adverse events between the study groups.
Contribution to the evidence: This study extends evidence from prior
trials on the safety and immunogenicity of the FMP1/AS02A vaccine to a
population that is representative of those most in need of an effective
vaccine—young African children. The results suggest that the vaccine
candidate should undergo further evaluation in trials examining vaccine
efficacy in a similar population.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.METHODS
Participants
The trial was conducted in Kombewa Division in the Kisumu
District of Nyanza Province of western Kenya. The study
subjects were drawn almost exclusively from the Luo ethnic
group living in low-land country near Lake Victoria. The Luo
are settled agriculturalists of Nilo-Saharan origin, most of
whom engage in low-income subsistence farming or ﬁshing.
In this region of holoendemic malaria transmission, most
infections (90%) are transmitted by mosquitoes of the
Anopheles gambiae complex and the infecting parasite species
is usually (95%) P. falciparum [23,24]. Transmission is intense,
with documented parasite prevalence during disease seasons
reaching as high as 83% among 1- to 4-y-old children [25] and
monthly clinical attack rates in the same ages as high as 54%
(unpublished data).
Data from a previous comprehensive census of Kombewa
Division, as well as from a more focused census done
immediately prior to recruitment, were used to identify
potential ﬁeld stations. This fairly comprehensive demo-
graphic database established how many eligibles (on the basis
of age) were present in the areas to be drawn from. All
parents known to have children in the relevant age groups
and living within a 1-mile (1.6-km) radius of each of 12 ﬁeld
stations were invited to participate in a brieﬁng.
Prior to enrollment in this study, a medical history, physical
examination, and screening laboratory tests were performed
on every subject to detect any underlying medical condition
that might confound clinical evaluation or data analysis. Males
and females were considered eligible for enrollment if they
were 12–47 mo old at the time of screening and in good health
and if a parent agreed to sign a written and witnessed
informed consent form and to remain in the study area for 12
mo. Exclusion criteria included any evidence of acute or
chronic medical conditions that might increase the risk to the
participating subject. Speciﬁc exclusion criteria included
prior receipt of an investigational malaria vaccine or of a
rabies vaccine; recent or planned use of any investigational
new drug (IND), vaccine, immunoglobulin, or any blood
product; use of immunosuppressant drugs within the previous
6 mo; conﬁrmed or suspected immunodeﬁciency; history of
splenectomy; administration, or anticipated administration,
of a vaccine not foreseen by the study protocol within 30 d of
the ﬁrst dose of vaccine (with the exception of tetanus toxoid);
and concurrent participation in another clinical trial.
Laboratory exclusion criteria were ﬁndings of serum alanine
aminotransferase (ALT) of .45 IU/L; serum creatinine of
. 1.1 mg/dL; absolute lymphocyte count (ALC) for 1-y-olds of
, 4.0 3 10
3/mm
3, for 2-y-olds of , 3.0 3 10
3/mm
3, and for
3-y-olds of , 2.0310
3/mm
3; platelet count of ,100,000/mm
3;
hemoglobin of , 8 g/dL; homozygosity for sickle cell disease
(SS) genotype (by protein gel electrophoresis); and malnu-
trition deﬁned as weight for height of ,  3 z-scores.
Participants were recruited under a human use protocol
approved by and executed in accordance with the guidelines of
the Ofﬁce of the Surgeon General, United States Army; the
Ethics Review Committee of the Kenya Medical Research
Institute (Kenya Ministry of Health); and the Human Subjects
Protection Committee of the Program for Appropriate Tech-
nology in Health (PATH). Informed consent was obtained from
all participants in accordance with all applicable guidelines.
Interventions
The expression, puriﬁcation, biochemical, and immunological
characterization of the Escherichia coli–produced, GMP-manu-
factured, FMP1 antigen have been described elsewhere [19], as
has the manufacture and packaging of AS02A [22]. Immedi-
ately prior to immunization, the contents of one syringe
preﬁlled with AS02A (approximately 0.6 mL) were injected
into a vial of lyophilized FMP1 antigen (approximately 64 lg).
The pellet of FMP1 was then dissolved by gently swirling the
vial to ensure complete dissolution of the contents (yielding a
milky white ﬂuid) to yield ﬁnal delivered volumes of 0.1, 0.25,
or 0.5 mL (for doses of 10, 25, or 50 lg, respectively).
The comparator vaccine, an inactivated rabies vaccine
(Imovaxt Rabies, produced by Aventis Pasteur, Lyon, France),
has been described elsewhere [22]. Immediately prior to
immunization, the complete contents of a preﬁlled syringe
containing diluent (1 mL of sterile water for injection) were
injected into a vial of lyophilized vaccine, and the pellet was
allowed to dissolve by gently swirling the vial to ensure
complete dissolution before withdrawing 1.0 mL of the
reconstituted rabies vaccine, a clear pink liquid.
Subjects were vaccinated by intramuscular injection alter-
nately into right or left anterolateral thigh muscles according
t oa0 - ,1 - ,a n d2 - m os c h e d u l e .T h et r i a lh a dt h r e e
immunization cohorts for purposes of dose escalation. Each
cohort contained 30 subjects that received 10, 25, or 50 lgo f
FMP1/AS02A and 15 subjects that received standard doses of
the rabies vaccine comparator. Each dosage cohort was age
stratiﬁed to ensure that any imbalance in safety and
reactogenicity rates was not due to a disproportion of young
children in any one cohort (Table 1).
An independent data and safety monitoring board (DSMB)
was appointed before the study began to review both the
.......................................................................................................................................................................................
Table 1. Numbers of Subjects by Cohort (Dosage Group), Study Arm (Vaccine Group), and Age Group
Cohorts (Dosage Groups) Receiving Test Vaccine (FMP1/AS02A) Receiving Comparator (Rabies) Vaccine
Dose 12–23 mo 24–35 mo 36–47 mo 12–23 mo 24–35 mo 36–47 mo
Low-dose cohort 10 lg1 0 1 0 1 0 5 5 5
Medium-dose cohort 25 lg1 0 1 0 1 0 5 5 5
High-dose cohort 50 lg1 0 1 0 1 0 5 5 5
Age group totals 30 30 30 15 15 15
Vaccine group totals 90 45
Grand total 135
doi:10.1371/journal.pctr.0010032.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Pediatric MSP-1 Phase Ib Trial in Western Kenyasafety data reports as the trial progressed and the data analysis
by Statistics Collaborative after study completion. DSMB
membership included a statistician and four senior clinical
research investigators with experience in conducting malaria
vaccine trials, one of whom was a Kenyan. An experienced
local clinician (Ambrose Misore, M.B.Ch.B.) served as the local
medical monitor (LMM), reviewed all serious adverse events
(SAEs) and safety data between dose escalations, and
functioned as the patient advocate. In addition, the trial was
monitored for regulatory compliance by representatives of
the United States Army Medical Materiel Development
Activity, GlaxoSmithKline Biologicals, and Pharmaceuticals
Product Development (a contract research organization based
in Wilmington, North Carolina, United States), all of whom
made several visits to the study site. Initial approval of the
study protocol and of subsequent protocol amendments was
granted to the investigators by the Ethical Review Committee
of the Kenya Medical Research Institute, Nairobi; by the
Human Subjects Protection Committee of PATH, Seattle,
Washington, United States; and by the United States Army
HSRRB. The study was done under a Food and Drug
Administration IND and was compliant with all relevant
International Conference on Harmonization guidelines.
Vaccinationsof the second andthirdcohorts werestaggered
fromeachotherby2wk(Table2).Asafetyreportwasproduced
priortoeachdoseescalation.TheLMMandtheDSMBreviewed
all adverse events (AEs) occurring in the 7 d immediately
following any vaccination that preceded a dose escalation.
WrittenapprovalfromtheLMMandconcurrencebytheDSMB
were required prior to any subsequent dose escalation.
Stoppingrulesweretobeinvokedwheneitherofthefollowing
observations was made: (1) . 20% of subjects with ‘‘severe’’
(grade3)generalAEs(notlocalAEs)relatedtothevaccine;or(2)
any SAE, including death, judged to be vaccine related.
Objectives
The primary objective was to assess the safety and reactoge-
nicity of the FMP1/AS02A malaria vaccine in malaria-exposed
12- to 47-mo-old children living in western Kenya. The
secondary objective was to assess the humoral immune
response to the FMP1/AS02A malaria vaccine in malaria-
exposed 12- to 47-mo-old children living in western Kenya.
Outcomes
The primary endpoints were (1) occurrence of solicited
symptoms (based on a standardized questionnaire) during a
7-d follow-up period after each vaccination (postvaccination
clinic visits occurred on study days 1, 2, 3, and 7 after each
vaccination); (2) occurrence of unsolicited symptoms during a
30-d follow-up period after each vaccination; and (3)
occurrence of SAEs during an 8-mo follow-up period
following the ﬁrst dose of study vaccine (i.e., 6 mo following
the last vaccination). The secondary endpoints were anti-
FMP1 (anti-MSP-142 3D7 strain antibody) titers as determined
by an enzyme-linked immunosorbent assay (ELISA) on study
days 0, 14, 30, 44, 60, 74, 90, 180, 270, and 364.
Assessmentofprimaryendpoints(safetyandreactogenicity).
Following each vaccination, subjects were followed for
occurrence of solicited symptoms for 7 d, unsolicited
symptoms for 30 d, and SAEs for 8 mo (i.e., 6 mo after the
last vaccination) or until resolution. Both local (injection-site
pain and swelling) and general/systemic (fever, drowsiness,
loss of appetite, and irritability/fussiness) symptoms were
assessed (Table 3). After the ﬁnal vaccination, subjects were
followed monthly at home by ﬁeld workers and were asked to
return to the clinic every 3 mo until the end of the study for
safety follow-up. An SAE was deﬁned as any untoward
medical occurrence that resulted in death, was life threat-
ening, resulted in persistent or signiﬁcant disability or
incapacity, or required in-patient hospitalization (or prolon-
gation of hospitalization). Important medical events that
might jeopardize a subject or might require intervention to
prevent one of the other outcomes listed above were
considered SAEs. Serum creatinine, ALT, white blood cell
count, lymphocyte count, platelet count, and hemoglobin
were determined on study days 0, 14, 30, 44, 60, 74, and 90.
Additional hemoglobin determinations were made on study
days 180, 270, and 364. Normal ranges were calculated on the
basis of previous data from the local pediatric population.
Assessment of malaria. A peripheral blood smear was
obtained from any subject who presented to the Walter Reed
Project’s Kombewa Clinic with fever, a history of fever within
48 h, or an illness that the attending doctor suspected might
be due to malaria infection. After Giemsa staining and
examination by oil-immersion light microscopy, detection of
asexual parasitemia of . 0 parasites/lL resulted in the
diagnosis and treatment for malaria.
Assessment of secondary endpoints (humoral responses).
Immunologysamples were collected on study days 0,14, 30, 44,
60, 74, 90, 180, 270, and 364; samples collected on study days 0,
30, and 60 were collected immediately prior to vaccination.
Immuneresponse to the FMP1/AS02A vaccine was determined
by anti-FMP1 ELISA endpoint titers reported in optical
density units (ODUs), the dilution yielding an ODU of 1.0 in
ourassay.Thisassayhasbeendescribedindetailelsewhere[22].
Sample Size
This trial represents the ﬁrst time to our knowledge that this
vaccine candidate has been evaluated in a pediatric pop-
ulation. Sample size was chosen after weighing the need to
detect any possible vaccine associated AEs against the need to
limit the number of subjects exposed to an investigational
product. Incorporation of the Imovaxt Rabies vaccine
comparison group enabled broad initial estimates of the
incidence of local and general side effects in a population
that suffers from signiﬁcant comorbidity from exposure to
endemic illnesses. The control cohort also served as a
comparator for the longitudinal immune responses to the
FMP1 antigen in a malaria-exposed population. Although
comparative statistics for the safety variables were calculated,
the study had low power to detect anything other than large
differences in the incidence of local and general side effects
between the vaccination groups.
.......................................................................................
Table 2. Timing of First, Second, and Third Vaccinations for
Each Cohort (Dosage Group) over 12 wk
Cohort Month 0 Month 1 Month 2 Month 3 Months 4–11
10 lg/rabies Screening 1st 2nd 3rd SAE follow-up
25 lg/rabies 1st 2nd 3rd
50 lg/rabies 1st 2nd 3rd
doi:10.1371/journal.pctr.0010032.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Pediatric MSP-1 Phase Ib Trial in Western KenyaWith sample sizes of 15, 30, and 45 (corresponding to the
sizes of groups within the trial), we have 90% power to detect
an AE that occurs in 14%, 7%, and 5% of the population,
respectively. The study was not powered to detect an immune
response because the primary focus of this trial was safety.
Randomization: Sequence Generation
A randomization list generated by Statistics Collaborative
contained sequential codes linked to a study vaccine assign-
ment. These codes were assigned to subjects in the order in
which they presented to the clinic on the day of ﬁrst
vaccination. Blocked blinded randomization was used with
stratiﬁcation for age and dosage groups. Fifteen subjects from
each age group were randomized into each of the three
cohorts (10 receiving the test article and ﬁve receiving the
comparator). Because of the very small sample sizes (Table 1),
these strata were not intended for analysis.
Randomization: Allocation Concealment
The only persons at the study site with access to the random-
ization assignments were the study drug manager, the clinic
pharmacist, and his assistant; it was necessary that these
individuals have access to the codes for preparation of test
articles. Each randomization assignment was sealed in a
unique, tamper-evident envelope, which was opened at the
timeasubjectpresentedfortheﬁrstvaccination.TheLMMalso
keptonesetoftherandomizationcodesinasealedenvelopein
the event that emergency unblinding became necessary.
Randomization: Implementation
Subjects were randomized in the order in which they
presented on the ﬁrst day of vaccination in a 2:1 ratio to
receive either FMP1/AS02A (90 subjects) or the comparator
vaccine (45 subjects). The subjects were enrolled by the study
drug manager, clinic pharmacist, and his assistant, and these
individuals assigned the subjects to their groups.
Blinding
Because the color and volumes of the reconstituted FMP1/
AS02A and comparator vaccines differed, the barrel of the
syringe was covered with opaque tape to mask its contents
and labeled with the subject identiﬁcation number and
randomization code. Subjects, parents, and the staff perform-
ing follow-up evaluations were all blinded. Immunizations
were carried out simultaneously in four separate consultation
rooms that were connected to a central pharmacy (the vaccine
preparation room) by small, closable service hatches. On
vaccination days, the prepared syringe was handed through a
service hatch to a vaccinator for vaccine administration. For
each subject, an identiﬁcation number, a randomization code
from a chart, and a randomization code on the syringe were
recorded on a vaccination form. Following vaccine admin-
istration, subjects were assessed and follow-up visits con-
ducted by a group of clinicians who had not been involved in
the vaccinations. The study investigators became unblinded
to treatment allocations in July 2005, after study completion
(which was September 2004).
Statistical Methods
Statistical analyses were performed by Statistics Collaborative
using SAS version 8.2 (SAS Institute, Cary, North Carolina,
United States). The incidence of solicited, unsolicited, and
serious AEs were compared using two-sided Fisher’s exact
tests without correction for multiplicity. Geometric mean
titers (GMTs) were calculated to assess immunogenicity at
each timepoint when titers were collected. The titer data
were transformed to a log10 scale and were modeled by
longitudinal mixed models to assess the effect of dose and age
on the mean level of the antibody responses over time. The
models used a spatial covariance structure, which takes into
account the number of study days between two measurements
when determining the correlation between them.
.......................................................................................................................................................................................
Table 3. Assessment of Symptom Intensities
Symptom Intensity (Grade) Intensity Definition
Pain at injection site 0 Absent
1 Minor reaction to touch
2 Cries/protests on touch
3 Cries when limb is moved/spontaneously painful
Swelling at injection site 0 0 mm
1 , 5m m
2 5–20 mm
3 . 20 mm
Fever (axillary temperature) 0 Absent
1 37.5 8C–38.0 8C
2 38.1 8C–39.0 8C
3 . 39 8C
Drowsiness 0 Behavior as usual
1 Easily tolerated
2 Interferes with normal activity
3 Prevents daily activity
Loss of appetite 0 Normal
1 Eating less than usual/no effect on normal activity
2 Eating less than usual/interferes with normal activity
3 Not eating at all
Irritability/fussiness 0 Behavior as usual
1 Crying more than usual/no effect on normal activity
2 Crying more than usual/interferes with normal activity
3 Crying that cannot be comforted/prevents normal activity
doi:10.1371/journal.pctr.0010032.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Participant Flow
A total of 590 parents of children were briefed; of these, 436
parents consented to screening. Of the 320 children who were
returnedforscreening,135(77girlsand58boys)wereenrolled
and randomized to one of the three dosage cohorts. Among
these were 25 children who were initially disqualiﬁed owing to
clinicalmalaria;however,theyweresubsequentlyenrolledafter
successful treatment and conﬁrmed cure. Of the 135 subjects
who received the ﬁrst vaccination, ﬁve did not receive the
secondvaccinationandanothereightdidnotreceivethethird.
Thus, 122 subjects received all three vaccinations; 83 of the 90
subjectswererandomizedtoreceiveFMP1/AS02Aand39ofthe
45 randomized to receive the rabies vaccine. The 13 incom-
pletely vaccinated subjects were evenly distributed among the
three dose cohorts (Figure 1). Because all of the 135 enrolled
subjects received at least one vaccination, all were to be
followed per protocol for the study duration and included in
the safety analyses. Twenty-ﬁve subjects withdrew prematurely
fromthestudy,approximately20%fromeachstudyarm;these
withdrawalswerealsoevenlydistributedacrosscohorts.Twelve
subjects had consent withdrawn by a parent or grandparent
because of family discord regarding participation in the study;
11subjectsmigratedoutofthestudyarea;onesubjectattended
the ﬁnal study visit during which the mother refused the blood
draw; and one subject died. With the exception of the last, no
subject was withdrawn from the study (as opposed to withheld
from further vaccinations) because of an AE.
Recruitment
Recruiting and enrollment occurred from 25 July through 12
September 2003. The study duration was approximately 12mo
for a subject with the last study visit on 19 September 2004.
Baseline Data
The study groups were comparable in baseline demography,
height, weight, and vital signs (temperature, pulse, respiratory
rate, and blood pressure). Baseline clinical laboratory meas-
urements other than ALC were consistent across study arms;
most measurements fell within the local normal range. Both
study arms had a number of subjects outside of the normal
range for ALC at the sampled timepoints, including prior to
receipt of the ﬁrst vaccination, but none of these was deemed
clinically signiﬁcant. Age, sex, height, weight, clinical labo-
ratory values, and antibody to FMP1 prior to the ﬁrst
vaccination are presented in Table 4 for the four study arms.
Numbers Analyzed
This study randomized 135 children (aged 12–47 mo) into
three cohorts of 45 subjects, each consisting of 30 children
who received FMP1/AS02A (10, 25, or 50 lg of FMP1 in 0.1,
0.25, or 0.50 mL of AS02A, respectively) and 15 children who
received the comparator vaccine. Each cohort contained 15
subjects, 10 receiving FMP1/AS02 and ﬁve the comparator, in
each of three age groups (12–23, 24–35, and 36–47 mo, or 1-,
2-, and 3-y-olds) for a total of 45 subjects in each age group
distributed among the three cohorts. The comparator groups
received rabies vaccine (Table 1). Each subject was to be
studied for approximately 12 mo. Safety analyses were
performed on an intention-to-treat cohort; immunogenicity
analyses were performed on an according-to-protocol cohort
that received all three vaccinations (106 subjects) (Figure 1).
Outcomes and Estimation of Safety and
Reactogenicity
Solicited symptoms. Both the test article and comparator
vaccines were well tolerated. No parent or child withdrew
from the study for a vaccine-related side effect. Table 5
summarizes the solicited signs and symptoms during the 7-d
follow-up periods after vaccinations. Both local symptoms
(pain and swelling) were deﬁned as vaccine-related AEs.
Subjects in all cohorts who received FMP1/AS02A experi-
enced more local symptoms than those who received the
comparator, and a dose-related response was apparent. The
largest percentage of these subjects experienced a local
reaction immediately following the ﬁrst vaccination (46% of
FMP1/AS02A subjects versus 2% of comparator subjects;
p-value, , 0.001); the percentages of subjects experiencing
local symptoms during second and third vaccinations were
lower in both study arms (respectively, 40% versus 9%;
p-value, , 0.001; and 37% versus 0%; p-value, , 0.001). The
most common local reaction at any time was pain at the site
of injection. Up to 38% of subjects receiving FMP1/AS02A
(percentages varied by dosage group) also experienced
injection-site swelling; however, no subject receiving the
comparator experienced swelling.
No sequence- or dose-related trends were apparent for
general solicited symptoms (Table 5). The most common
general symptoms in both study arms were fever and loss of
appetite. No instance of drowsiness occurred during any
solicited symptom follow-up period. Fever was seen after
vaccination in all dosage groups, with the highest rates being
seen in the 50-lg dosage group. Loss of appetite and
irritability/fussiness were seen at similar rates in all dosage
groups and the comparator vaccine.
Fewsubjectsexperiencedgrade3symptoms(Table5).Grade
3 pain at the injection site was seen sporadically with the
second and third immunization in the 25- and 50-lg dosage
groups of FMP1/AS02A. Grade 3 fever was seen sporadically in
both the test article and the comparator vaccine.
Unsolicited symptoms. Unsolicited symptoms were re-
corded for 30 d following each vaccine administration and
were categorized by a modiﬁed World Health Organization
Adverse Reactions Terminology (WHOART) AE coding
system. There were no differences by group or by cohort in
the proportions of subjects experiencing an unsolicited
symptom. All but one of the enrolled children experienced
at least one unsolicited symptom during a follow-up period,
and most experienced an unsolicited symptom during each of
the three follow-up periods (77%–97% for FMP1/AS02A and
80%–100% for the comparator). The most common unsoli-
cited symptoms were upper respiratory tract infections
(URTIs) and malaria.
Approximately 80% of subjects in each study arm
experienced at least one URTI during the three 30-d
postimmunization follow-up periods. There was no indica-
tion that vaccinated groups had any increased risk of
developing clinical malaria.
For unsolicited symptoms, vaccine relatedness was deter-
mined by temporal relationship to a vaccination with absence
of any reasonably explanatory comorbidity. Very few vaccine-
related unsolicited symptoms occurred during the post-
immunization follow-up period (ﬁve and one among FMP1/
AS02A and comparator recipients, respectively). These
www.plosclinicaltrials.org November | 2006 | e32 0006
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doi:10.1371/journal.pctr.0010032.g001
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Pediatric MSP-1 Phase Ib Trial in Western Kenyasymptoms were mostly limited to injection-site reactions that
differed from those elicited during the immediate follow-up
period. They included a case of hyperpigmentation in the
comparator group and three cases of fever by history, one of
induration, and one of eczema in the FMP1/AS02A group. The
last mentioned was a nonpruritic skin rash developing in the
right ﬂank area about 50 min after a second vaccination of the
10-lg dose of FMP1/AS02A. Initially presenting with a plaque-
like appearance, these lesions developed a follicular eczem-
atous pattern that then resolved over a few days. This child
had been noted to have similar (albeit smaller) dermatitic or
eczematous lesions prior to the ﬁrst vaccination. A third
vaccination was withheld from this subject. One grade 3
unsolicited symptom occurred during the postimmunization
follow-up period, a 25-lg FMP1/AS02A subject experiencing
grade 3 malaria beginning 2 d after receiving the ﬁrst
vaccination. (Grade 3 was deﬁned as an event severe enough
to prevent normal daily activities.) No subject in the study
experienced a grade 3 vaccine-related, unsolicited symptom.
Serious and unexpected AEs. Serious and unexpected AEs
were collected on a real-time basis through study day 240. No
SAE was judged causally related to a vaccination. Seven
documented SAEs occurred during this period: four in the
FMP1/AS02A group and three in the comparator group. In the
former group, two children in the 10-lg dosage cohort
experienced convulsions 17 and 189 d after second and third
vaccinations, respectively; one child in the 50-lg dosage group
experienced convulsions 12 d after the third vaccination. (All
convulsions were febrile, malaria-associated seizures.)
A 37-mo-old female acquired malaria 26 d after receiving a
third dose of 10 lg of FMP1/AS02A, was treated, and
recovered. She developed hepatitis and severe anemia 7 d
later. She died 62 d after her third vaccination, following
several hospitalizations and blood transfusions. In this
subject, an extravascular hemolysis caused severe organo-
megaly with secondary thrombocytopenia and hypersplen-
ism, along with a possible partial obstruction of biliary
outﬂow. The death of this subject led to a thorough review of
.......................................................................................................................................................................................
Table 4. Demographic, Clinical, and Laboratory Baseline Characteristics of 135 Enrolled Subjects Prior to First Vaccinations
Characteristics Imovaxt
(n ¼ 45)
Cohort A: FMP1/AS02A
(n ¼ 30)
Cohort B: FMP1/AS02A
(n ¼ 30)
Cohort C: FMP1/AS02A
(n ¼ 30)
Mean age in months (SD) 29.3 (10.4) 28.5 (9.6) 29.5 (10.9) 29.9 (9.9)
Number of males (%) 18 (40%) 12 (41%) 11 (37%) 17 (57%)
Mean height in centimeters (SD) 83.7 (8.2) 84.7 (7.0) 84.8 (9.0) 83.1 (6.9)
Mean weight in kilograms (SD) 11.8 (2.5) 12.2 (2.0) 12.0 (2.5) 11.7 (1.9)
Mean WBC 3 10
3/lL (SD) 10.0 (4.3) 9.5 (3.0) 10.1 (2.9) 9.4 (2.4)
Mean Hgb (g/dL) (SD) 10.1 (1.4) 9.7 (1.2) 10.1 (1.4) 10.0 (1.2)
Mean platelets 3 10
3/lL (SD) 330 (133) 329 (206) 334 (165) 346 (131)
Mean ALC 3 10
3/lL (SD) 5.6 (2.1) 5.5 (2.1) 5.9 (2.0) 5.6 (1.9)
Mean creatinine (mg/dL) (SD) 0 (N/A) 0 (N/A) 0 (N/A) 0 (N/A)
Mean ALT (U/L) (SD) 19.3 (7.0) 19.2 (8.1) 25.5 (33.4) 20.2 (13.40)
GMT anti-FMP1 antibody titer (95%CI) 2369 (799-7162) 2920 (970-8786) 2737 (1492–5023) 2387 (1088–5238)
Abbreviations: Hgb, hemoglobin; N/A, not applicable; SD, standard deviation; WBC, white blood cell count
Cohort A ¼ 10 lg; Cohort B ¼ 25 lg; Cohort C ¼ 50 lg
doi:10.1371/journal.pctr.0010032.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 5. Number (Percentage) of Subjects Experiencing Solicited Signs and Symptoms during the 7-d Follow-Up after Each
Vaccination by Study Arm
Study Arm Imovaxt FMP1/AS02A
Vaccination Number 1st 2nd 3rd 1st 2nd 3rd
Dosage Group (lg) Approved Dose 10 25 50 10 25 50 10 25 50
Number of Subjects 45 43 39 30 30 30 30 29 28 28 29 26
Local (Injection site)
Pain 1 (2) 4 (9) 0 (0) 7 (23)* 13 (43)* 18 (60)* 4 (13) 12 (41)* 17 (61)* 1 (4) 11 (38)* 19 (73)*
Grade 3 pain 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 1 (4) 0 (0) 1 (3) 0 (0)
Swelling 0 (0) 0 (0) 0 (0) 4 (13)* 4 (13)* 2 (7)* 2 (7) 2 (7)* 7 (25)* 0 (0) 3 (10)* 10 (38)*
Grade 3 swelling 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
General (systemic)
Fever 10 (22) 7 (16) 5 (13) 7 (23) 8 (27) 12 (40) 6 (20) 3 (10) 7 (25) 3 (11) 4 (14) 5 (19)
Grade 3 fever 0 (0) 4 (10) 0 (0) 2 (7) 1 (3) 0 (0) 1 (3) 1 (3) 0 (0) 1 (4) 0 (0) 0 (0)
Drowsiness 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Loss of appetite 9 (20) 6 (14) 5 (13) 7 (23) 6 (20) 6 (20) 4 (13) 5 (17) 4 (14) 1 (4) 3 (10) 3 (12)
Irritability/fussiness 0 (0) 1 (2) 0 (0) 0 (0) 2 (7) 0 (0) 1 (3) 1 (3) 0 (0) 1 (4) 0 (0) 2 (8)
Grade 3 symptoms
Local 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 1 0 (0) 1 0 (0)
General 0 (0) 4 0 (0) 2 1 0 (0) 1 1 0 (0) 1 0 (0) 0 (0)
* p-value (Fisher’s exact test) significant (,0.05) between cohorts
doi:10.1371/journal.pctr.0010032.t005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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pediatric hematology consultant not previously associated
with the study. After considering all potential etiologies
(including Epstein–Barr virus, parvovirus B19, and others)
that could have precipitated such a clinical course and the
clinical context (e.g., the long interval between vaccination
and onset), it was concluded that there was not a likely causal
biological connection between the immunization and the
preterminal course and death. In accordance with the study
protocol, the principal investigator’s judgment was that
‘‘there are other, more likely causes and administration of
the study vaccine is not suspected to have contributed to the
adverse event.’’ Her death was judged not related to the study
vaccine, but rather to autoimmune hemolytic anemia, most
likely secondary to a viral infection, causing ﬁrst hepatitis and
then an unusual warm reactive immunoglobulin G. The
clinical course and the temporal association are here
reported so that in the event of similar instances, this
information will be readily available.
In the comparator group, one subject experienced febrile,
malaria-associated convulsions; one, an episode of severe
bronchospasm; and one, an intestinal obstruction due to
ascariasis. One unexpected AE occurred during the study: a
subject from the comparator group experienced a markedly
elevated ALT level and was diagnosed with hepatitis A. The
subject was excluded from the third vaccination to eliminate
the possibility of confounding the assessment of safety
following subsequent vaccinations. In addition, two subjects
from the FMP1/AS02A group developed phimosis, leading to
elective hospitalizations and circumcisions.
Laboratory parameters. Blood (venous samples from arms)
for laboratory measurements (white blood cell count,
hemoglobin, platelet count, ALC, creatinine, and ALT) was
collected at baseline (study day 0) and on study days 14, 30, 44,
60, 74, and 90. Group mean safety laboratory values were
generally unchanged in the 30-d postimmunization follow-up
periods. The majority of subjects had all values within normal
range. However, both vaccine and comparator groups had a
number of subjects outside of the normal range of ALCs,
including timepoints prior to ﬁrst vaccination; none was
judged to be clinically signiﬁcant.
The protocol speciﬁed that each child was to receive 10
hemoglobin determinations occurring at the seven time-
points cited above and on study days 180, 270, and 364. None
of the 90 children who received FMP1/AS02A had a
hemoglobin level below the local lower limit of normal (9.75
g/dL 6 2 SD, 6.5–13.0 g/dL); one of the 45 children enrolled in
the comparator arm fell below this limit at one timepoint.
Outcomes and Estimation of Immunogenicity
As expected of a subject population that had been highly
exposedtomalariapriortovaccination,nobaselineanti-FMP1
titer fell below the limit of detection. Baseline GMTs were
comparable across study arms and dosage cohorts, ranging
from approximately 1,000 to 3,000 ODUs. The overall baseline
GMT in thousands (across all study groups) was 2.3 (95%
conﬁdenceinterval[CI]of1.7,3.2).Afterthreevaccinations,no
increase in antibody response was observed in subjects who
received the comparator; however, antibody response in-
creased with increasing dosage level of FMP1/AS02A (Figure
2). GMT peaked 2 wk after the third immunization (study day
74), at which time the GMTs (in thousands) were 10 (95%CI, 6–
17), 43 (95%CI, 29–65), and 58 (95%CI, 38–89) ODU in the 10-
lg, 25-lg, and 50-lg groups, respectively. GMT in the
comparator group was 1.5 with a 95%CI of 0.8–2.7. The study
day 90 GMT (in thousands) for the 10-lg dosage cohort
remained constant at 10 (95%CI, 6–18), but the study day 90
GMT for the 25- and 50-lg dosage cohorts dropped to 27
(95%CI, 18–41) and 40 (95%CI, 25–62), respectively. From
study day 180, the antibody levels in the 25- and 50-lg dosage
groups begin to diminish; however, by study day 364 they still
maintained higher antibody levels than the subjects in the 10-
lg dosage group and in the comparator group.
Titer ratio plots indicate the percentage of subjects
Figure 2. Anti-FMP1 GMTs over Time, by Vaccine Group
Arrows indicate vaccination time points.
doi:10.1371/journal.pctr.0010032.g002
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baseline values (Figure 3). At study day 74, the graph indicates
that approximately 50% of subjects receiving the 10-lg dose
of FMP1/AS02A experienced at least a 4-fold rise, and
approximately 50% of subjects receiving the 25- or 50-lg
dose experienced at least a 16-fold rise. At study day 364,
approximately 50% of subjects in the 25- and 50-lg dose
cohorts of the FMP1/AS02A group showed at least a 4-fold
rise in antibody titer, and at least 20% of these two cohorts
maintained a 16-fold rise.
Longitudinal models. To assess the effect of dose and age
group on the mean level of antibody responses over time, we
estimated least-square means and standard errors of log10-
transformed values of anti-FMP1. All subjects were included
in the model (data not shown). Tests of main effects (dose and
age group), the age group3dosage level interaction, and dose
response were performed. The results from the model for all
randomized subjects showed the immune response differed
among dosage levels (F3,995 ¼ 11.22; p , 0.001). Neither the
age group 3dosage level interaction nor the age group main
effect is statistically signiﬁcant (F6,995 ¼ 1.02, p ¼ 0.41; F2,995 ¼
0.25, p ¼ 0.78, respectively), providing no evidence that a
subject’s age inﬂuences the vaccine’s immunogenicity over
time. A highly signiﬁcant linear trend in dose response was
observed (F1,995 ¼ 29.65; p , 0.001). The 50-lg dosage group
had a higher response than the 10-lg dosage group (F1,995 ¼
6.68; p¼0.010); however, the 25- and 50-lg dosage groups did
not show a signiﬁcant difference (F1,995 ¼ 0.2; p ¼ 0.65).
DISCUSSION
Interpretation
This phase Ib dose-escalation and safety trial provided clear
evidence of the safety and tolerability of 10-, 25-, and 50-lg
doses of FMP1/AS02A when given to young children subject
to intense malaria transmission in western Kenya. Although
subjects allocated to the test article arm experienced more
solicited local symptoms, the proportion affected is compa-
rable to the symptoms seen with another vaccine antigen
formulated with the same adjuvant system [6]. The frequency
of solicited general symptoms was similar among the groups,
and neither vaccine group experienced signiﬁcant numbers
of local or general solicited grade 3 reactions. The unsolicited
symptoms experienced were quite similar in type, number,
and intensity between the two vaccines, with malaria and
URTI predominating. Laboratory parameters were compara-
ble throughout the study. No local or systemic allergic event
occurred. The seven SAEs occurring during the 8-mo
observation period were evenly divided between test article
and comparator arms, with none adjudged causally related to
receipt of a vaccine. Further evidence of the general
tolerability of FMP1/AS02A in this population is the
equivalent dropout rate in the two arms.
The 25- and 50-lg doses generated a humoral immune
response that was of greater magnitude than the 10-lg dose
in this pediatric population. The previous FMP1/AS02A adult
study at Kombewa [22] found a statistically signiﬁcant
antibody response to the same three-dose regimen in a
semi-immune adult population that had a substantial baseline
anti-FMP1 antibody titer. In that study, titers peaked 90 d
after receipt of 50 lg of FMP1/AS02A with an average 2.7-fold
increase over baseline levels. This immunogenicity of the
vaccine in adults may have been masked by the high levels of
preexisting antibody in that semi-immune population; this
was supported by the observation that the greatest rise in
antibody was seen in subjects with the lowest baseline levels.
The present study conﬁrms our anticipation that this vaccine
candidate would induce an even greater increase in anti-
FMP1 titers when administered to children with less malaria
exposure and lower baseline titers.
The waning of antibody levels in the 25- and 50-lg dosage
groups after study day 74 is congruent with previous
experience with FMP1. Signiﬁcantly, by study day 364, the
25- and 50-lg dosage groups maintained higher antibody
levels than subjects in the 10-lg dosage and comparator
groups. It is not clear what effect boosting from natural
exposure had on the magnitude and persistence of the
antibody response, but the anti-FMP1 response in the rabies
comparator group did not signiﬁcantly increase over the
year-long observation period. The results from the log10-
transformed linear modeling for all randomized subjects
showed statistically convincing evidence of a dose-response
relationship to antibody response.
Consistent with our ultimate goal of allowing administra-
tion of a malaria vaccine as part of the World Health
Organization’s Expanded Programme on Immunisation (EPI)
to infants at greatest risk of malaria, we have here followed up
the previous year’s trial of FMP1/AS02A in adults in
Kombewa [22] with another EPI-compatible 0-, 1-, and 2-mo
schedule. This brisk schedule has now been shown to be well
tolerated in both trials and was not associated with any new
or higher incidence of postvaccination symptoms compared
to trials of FMP1/AS02A given on a 0-, 1-, and 3-mo schedule
in healthy malaria-naı ¨ve adults in the United States [21].
Reports of experimentally induced, malaria-associated
anemia in Aotus monkeys subjected to prolonged P. falciparum
parasitemia have raised concern that malaria vaccines
eliciting immunity that controls, but does not eliminate,
parasitemia might themselves increase the risk of anemia in
endemic human populations [26]. In the previous year’s adult
study, hemoglobin levels were stable in both test article and
comparator groups for 365 d. Results of the present study are
similarly reassuring in indicating that hemoglobin levels do
not deteriorate in children, even when they are exposed to
high levels of malaria transmission after vaccination. Indeed,
slight continuous increases in hemoglobin levels occurred in
all groups, perhaps because of the enhanced medical care
provided to these study subjects.
Generalizability
The study population selected for this trial was chosen as
representative of the target population for a malaria vaccine:
at-risk, malaria-experienced children living in an area of
endemic, holoendemic, or epidemic malaria. As the primary
Figure 3. Reverse Cumulative Plot of Anti-FMP1 Titer Ratios, by Dose Cohort, for Subjects Receiving All Three Vaccinations
(A) Ratios are depicted comparing study day 0 titers to study day 74.
(B) Ratios are depicted comparing study day 0 titers to study day 364.
doi:10.1371/journal.pctr.0010032.g003
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objective of the trial centered upon evaluation of safety and
reactogenicity, results should be broadly generalizable to
children of the representative age groups. Results pertaining
to the secondary objective (evaluation of immunogenicity)
should be generalizable to children of these age groups
exposed to P. falciparum infections at levels obtaining in the
study area, but may not be generalizable to children under
other transmission intensities.
Overall Evidence
Along with the previous year’s adult trial, this trial accom-
plishes the ﬁrst two of the three immediate goals of the
clinical development plan [27] for FMP1/AS02A, namely,
expansion of the safety and immunogenicity proﬁle in
endemic populations and dose exploration of the test article
in children. The third goal—determination of the prelimi-
nary efﬁcacy of this vaccine for reduction of clinical malaria
in children at risk of disease—awaits the outcome of a phase
IIb efﬁcacy trial. On the basis of preliminary presentations of
the results included here, this proposed efﬁcacy trial received
the endorsement of the DSMB and the relevant institutional
review boards in mid-2004 and is currently underway in
Kombewa. Results should be available by the end of 2006.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0010032.sd001 (255 KB PDF).
Trial Protocol
Found at doi:10.1371/journal.pctr.0010032.sd002 (1.0 MB DOC).
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